Teladoc Health has introduced a groundbreaking technology that combines artificial intelligence (AI) and real-time monitoring to enhance patient safety in hospitals. This innovative solution, known as Virtual Sitter, is designed to help hospital staff detect when a patient is at…
In observance of World AIDS Day (WAD) 2024 on December 1, AHF UK will host a commemorative event on Monday, December 2, 2024, from 9:30 a.m. to 3:00 p.m. at Croydon University Hospital (530 London Road, Thornton Heath, Surrey, CR7…
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global leader in precision genetic medicine for rare diseases, announced on November 29, 2024, the granting of equity awards to 14 new employees who joined the company in November 2024. These equity awards, which…
The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), has announced its first round of grant recipients for The Cigna Group Health Equity Impact Fund. This initiative will distribute $9 million over the next three years…
AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, has announced that the U.S. Food and Drug Administration (FDA) has approved Rapiblyk™ (landiolol) for the treatment of supraventricular tachycardia (SVT), including atrial fibrillation and atrial flutter, in critical care…
Galderma recently announced that the full results from the Phase III OLYMPIA 1 trial, which evaluated the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology. The data from this trial, in conjunction…
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today revealed plans to relocate its QIAstat-Dx operations to a new facility in Esplugues de Llobregat, near Barcelona. This move is part of a multi-year investment aimed at expanding and strengthening the company’s…
Hippocratic AI, the company pioneering the first safety-focused Large Language Model (LLM) for healthcare, has announced the issuance of its first patent, US Patent 12,142,371, granted by the US Patent Office this month. This patent covers key innovations integrated into…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company set to rebrand as BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell…
Aulos Bioscience, an innovative immuno-oncology company focused on developing potentially groundbreaking IL-2 therapeutics to revolutionize cancer care, has announced the dosing of its first patient in a Phase 2 clinical trial. The trial evaluates the combination of AU-007, avelumab (a…
